CETYL MYRISTOLEATE: The real arthritis cure

In addition to medical journals, the ideas for the vita-nutrient therapies I use in my practice and report on in this book often come from the medical meetings I attend. Two organizations –

1. FAIM (Foundation for the Advancement of Innovative Medicine), of which I was the founding president,
2. АСАМ (American College of Advancement in Medicine) – provide excellent forums where breakthroughs in complementary medicine are first presented.

Doctors at both recent meetings were abuzz with reports that a new natural, nontoxic treatment was now available that will replace the standard pharmacological treatments for all forms of arthritis. The nutritional substance is called cetyl myris- toleate, or CMO, for short.

I asked its proponents to show me the literature published about CMO, and they said that although none had yet been published, an interesting study was awaiting publication. I reviewed that paper and found it to be so promising that, having ascertained that CMO was perfectly safe, I began using it on those patients of mine who were still handicapped by rheumatoid or osteoarthritis.

THE EUROPEAN STUDY

Over four hundred patients entered the study, and two hundred of them were treated with CMO. About one hundred of the latter also were given companion treatments (glucosamine sulfate, cartilage extract and sea cucumber). Patients with osteoarthritis and rheumatoid arthritis were in both groups. Compared with untreated arthritis patients, only 14 per cent of whom showed any improvements, the CMO users benefitted 63 per cent of the time.

When the three helpers were added to the treatment, the improvement rate soared to 87 per cent. Side effects were minor at worst. If the results hold up, this programme alone could qualify as the treatment of choice for all forms of arthritis.

CMO comes from such animal sources as sperm whales, mice and beavers. The compound, a union of the fatty acid myristoleic acid and cetyl alcohol, lubricates joints, suppresses inflammation and curbs the autoimmune reaction that targets the body’s own joints.
CMO may prove useful in a variety of inflammatory conditions. Since none of the patients I have prescribed it for experienced any adverse reactions and many have reported rather gratifying symptom relief, I feel it is quite appropriate to explore these possibilities with patients experiencing major discomfort.

SUPPLEMENT SUGGESTIONS

I have been using the same protocol as in the European study, which involves a total of 180 capsules, each containing 100 mg of cetyl myristoleate per capsule. The capsules may be administered in a course of thirty to forty-five days (six to four daily would be used) along with the companion nutrients. After two weeks some relief of symptoms is usually noted. The initial teaching was that CMO treatment need not be resumed unless or until symptoms return, but I am more inclined to prescribe a maintenance dose of two to four capsules daily.